Keith Murphy is Founder, CEO, and Chairman of Viscient Biosciences, which leverages the power of 3D bioprinting in drug discovery, focused on NASH and other disease areas through advanced biological models. Prior to Viscient, Mr. Murphy co-founded Organovo, the world’s premier 3D Bioprinting company of which he is the former CEO and Chairman Emeritus, in 2007 and led all company operations until 2017. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and corporate partnerships, including major alliances with Astellas and Merck. The company started trading on NYSE in 2013, and since going public the company has focused on the development of three-dimensional liver, kidney, and cancer tissues. The most advanced program, liver tissue, has grown to encompass a range of applications from commercial use for pharmaceutical toxicology prediction to the preclinical development of human 3D liver patches for transplant patients. Prior to co-founding Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($3B+ annual sales). He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.
Subscribe to our newsletter